Is Arcturus Therapeutics Holdings Inc. (ARCT) a Buy, Sell, or Hold?
NASDAQ : ARCT
Arcturus Therapeutics Holdings Inc.
$5.76 USD
-$0.16 (-2.7%)
- Volume
- 266.6K
- Average Volume
- 475.6K
- Market Capitalization
- $163.72M
- P/E Ratio
- -2.04
- Dividend Yield
- 0.00%
- Price Target
- $25.00
- Year High
- $24.17
- Year Low
- $5.50
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.31
Company Overview
NASDAQ
Joseph E. Payne
Biotechnology
Healthcare
ARCT
111
US
USD
Liquidity Metrics
0.13
6.31
6.31
6.15
0.00
Sales & Valuation
$67.22M
3.61
0.86
-2.78
-2.07
Profitability
-$2.4
-$65.78M
-173.47%
-173.47%
-36.55%
-32.06%
P/E Metrics
-2.04
0.13
0.13
Analyst Price Target & Rating
$25.00
$25.00
$25.00
2/5
21 Analysts
-76.96%
Financial Health Scores
-1.15
2/9
$182.51M
$245.41M
$54.05M
-$70.41M
Key Metrics (TTM)
-$23.67M
-0.52
0.35
6.31
-36.55%
-41.43%
-48.06%
-35.97%
-363 days
Company Executives
| Name | Title |
|---|---|
| Ye Zhang | Chief Regulatory & Quality Assurance Officer |
| Kevin T. Skol | Chief Business Officer |
| Dennis Mulroy | Chief Financial Officer |
| Igor Smolenov | Chief Development Officer |
| Natash O. Bowman | Chief Human Resources Officer |
| Neda Safarzadeh | Vice President and Head of IR/PR & Marketing |
| Padmanabh Chivukula | Founder, Chief Scientific Officer, Chief Operating Officer & Secretary |
| Joseph E. Payne | Founder, President, Chief Executive Officer & Director |
| Joseph Roberts | Principal Accounting Officer & Controller |
| Lance Kurata | Chief Legal Officer |
Poll Results
No votes yet today — be the first to share your view!
About Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragen ... yx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.
2026-07-28 16:01:00
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for the quarter ended June 30, 2026, after the market close on Thursday, Aug 6th and will also host a conference call and webcast at 4:30 pm Eastern Time on Aug 6, 2026. Arcturus Therapeutics Second Quarter 2026 Earnings.
Financial Review: Arcturus Therapeutics (NASDAQ:ARCT) vs. Zenas BioPharma (NASDAQ:ZBIO)
2026-07-28 01:15:17
Zenas BioPharma (NASDAQ: ZBIO - Get Free Report) and Arcturus Therapeutics (NASDAQ: ARCT - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, dividends, earnings, institutional ownership and profitability. Earnings and Valuation This table compares Zenas
2026-07-26 01:59:19
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eleven analysts that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, six have issued a buy recommendation and one has
2026-07-21 03:16:02
Amova Asset Management Americas Inc. grew its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) by 12.9% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,288,935 shares of the biotechnology company's stock after purchasing an additional 262,347
Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
2026-07-20 16:01:00
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following investor conference in Boston, Massachusetts: Canaccord Genuity 46th Annual Growth Conference (Fireside Chat) Tuesday, August 11, 2026 (12:00 p.m. ET) Webcast link can be found under Investor Relations/Events section.
Arcturus: Now That It's Come This Low, It's Time To Buy And Hold
2026-07-20 11:38:03
Arcturus has dropped off enough to make it a net-cash stock - a stock trading for less its current asset value with all liabilities subtracted. A peer group of similar issues that I have rated here on Seeking Alpha has strongly outperformed the S&P 500 even through one of the strongest bull markets in history. This and the combination of a revenue generating asset portfolio and promising pipeline make Arcturus a compelling opportunity.
Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar?
2026-07-03 08:12:13
Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Arcturus Picks Thermo Fisher To Support Cystic Fibrosis Therapy
2026-07-02 11:32:58
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is collaborating with Thermo Fisher Scientific Inc. (NYSE:TMO) to support the Phase 3 development and potential commercialization of ARCT-032, the company's investigational messenger RNA therapy for cystic fibrosis.
Frequently Asked Questions
-
What is the current Arcturus Therapeutics Holdings Inc. (ARCT) stock price?
-
Arcturus Therapeutics Holdings Inc.(NASDAQ:ARCT) stock price is $5.76 in the last trading session. During the trading session, ARCT stock reached the peak price of $24.17 while $5.5 was the lowest point it dropped to. The percentage change in ARCT stock occurred in the recent session was --2.7% while the dollar amount for the price change in ARCT stock was -$0.16.
-
ARCT's industry and sector of operation?
-
The NASDAQ listed ARCT is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ARCT?
-
Ye Zhang | Chief Regulatory & Quality Assurance Officer
Kevin T. Skol | Chief Business Officer
Dennis Mulroy | Chief Financial Officer
Igor Smolenov | Chief Development Officer
Natash O. Bowman | Chief Human Resources Officer -
How many employees does ARCT have?
-
Number of ARCT employees currently stands at 111. ARCT operates from 10628 Science Center Drive, San Diego, CA 92121, US.
-
Link for ARCT official website?
-
Official Website of ARCT is: https://arcturusrx.com
-
How do I contact ARCT?
-
ARCT could be contacted at phone #858 900 2660 and can also be accessed through its website. ARCT operates from 10628 Science Center Drive, San Diego, CA 92121, US.
-
How many shares of ARCT are traded daily?
-
The average number of ARCT shares traded daily for last 3 months was 475.6K.
-
What is the market cap of ARCT currently?
-
The market value of ARCT currently stands at $163.72M with its latest stock price at $5.76